CY CYRX CryoPort, Inc. Loading... : Bullish and Bearish Analyst Opinions

Cryoport supports 766 clinical trials and 21 commercial therapies with >70% market share in cell/gene therapy cold chain. FDA regulatory moat due to integration into therapy filings. Pivoted to high-margin platform model after offloading courier to DHL. As CGT therapies scale and fertility preservation demand grows (Cryostork), the recurring revenue model becomes a compounding growth story. The stock is still below 2021 hype levels despite fundamentals improving. Cryoport is the infrastructure backbone for a nascent but exploding therapy class, with a regulatory lock-in that competitors cannot easily replicate. Slower-than-expected CGT adoption; regulatory changes; competition from UPS cold chain or in-house logistics.